Share Price, page-11261

To suggest that a share buy-back would require a capital raising is ludicrous in my opinion.

Neuren with its substantial cash reserves and increasing cash-flow are quite capable of walking and chewing gum at the same time. They have the financial means to fund two Phase 3 trials and to conduct a modest share buy-back.

The way the market is under-appreciating the underlying value of NEU means that I now favour a share buy-back. Even a modest $10m would do the trick and send multiple positive messages to the market and potential partners and acquirers.